专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008041053A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING 审中-公开
标题翻译： VEGF受体和HGF受体信号的抑制剂
公开(公告)号：WO2008041053A2
公开(公告)日：2008-04-10
申请号：PCT/IB2006004306
申请日：2006-05-19
申请人： METHYLGENE INC , SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY , GAUDETTE FREDERIC , ISAKOVIC LJUBOMIR , WAHHAB AMAL , GRANGER MARIE-CLAUDE , BERNSTEIN NAOMY
发明人： SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY , GAUDETTE FREDERIC , ISAKOVIC LJUBOMIR , WAHHAB AMAL , GRANGER MARIE-CLAUDE , BERNSTEIN NAOMY
CPC分类号： C07D495/04
摘要： The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
摘要翻译：本发明涉及VEGF受体信号传导和HGF受体信号转导的抑制。本发明提供了用于抑制VEGF受体信号传导和HGF受体信号传导的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法

2. 发明申请

WO2008035209A3 QUINOLINE AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY 审中-公开
标题翻译：喹啉和喹唑啉衍生物作为蛋白酪氨酸激酶活性的抑制剂
公开(公告)号：WO2008035209A3
公开(公告)日：2011-03-03
申请号：PCT/IB2007003264
申请日：2007-05-30
申请人： METHYLGENE INC , RAEPPEL STEPHANE , CLARIDGE STEPHEN WILLIAM , SAAVEDRA OSCAR MARIO , VAISBURG ARKADII , DEZIEL ROBERT , ZHAN LIJIE , MANNION MICHAEL , GAUDETTE FREDERIC , ZHOU NANCY Z , ISAKOVIC LJUBOMIR
发明人： RAEPPEL STEPHANE , CLARIDGE STEPHEN WILLIAM , SAAVEDRA OSCAR MARIO , VAISBURG ARKADII , DEZIEL ROBERT , ZHAN LIJIE , MANNION MICHAEL , GAUDETTE FREDERIC , ZHOU NANCY Z , ISAKOVIC LJUBOMIR
IPC分类号： C07D401/12 , A61K31/4709 , A61K31/517 , A61K31/5377 , A61P35/00 , C07D401/14 , C07D403/12 , C07D413/14
CPC分类号： C07D401/12 , C07D401/14 , C07D403/12 , C07D413/14 , C12N9/1205
摘要： The invention relates to quinoline and qumazoline derivatives that inhibit protein tyrosine kinase activity In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling The invention also provides compositions and methods for treating cell proliferative diseases and conditions
摘要翻译：本发明涉及抑制蛋白酪氨酸激酶活性的喹啉和喹唑啉衍生物。具体地，本发明涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，导致受体信号传导的抑制，例如VEGF受体信号传导的抑制和 HGF受体信号传导更具体地，本发明涉及用于抑制VEGF受体信号传导和HGF受体信号传导的化合物，组合物和方法本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法

3. 发明申请

WO2008073142A8 NOVEL INHIBITORS OF BETA-LACTAMASE 审中-公开
标题翻译： β-LACTAMASE的新型抑制剂
公开(公告)号：WO2008073142A8
公开(公告)日：2009-01-29
申请号：PCT/US2007011979
申请日：2007-05-21
申请人： MERCK & CO INC , METHYLGENE INC , DININNO FRANK , HAMMOND MILTON L , DYKSTRA KEVIN , KIM SEONGKON , TAN QIANG , YOUNG KATHERINE , HERMES JEFFREY DONALD , CHEN HELEN , RAEPPEL STEPHANE , MANNION MICHAEL , GAUDETTE FREDERIC , VAISBURG ARKADII , RAHL JUBRAIL , GEORGOPAPADAKOU NAFSIKA , ZHOU NANCY Z
发明人： DININNO FRANK , HAMMOND MILTON L , DYKSTRA KEVIN , KIM SEONGKON , TAN QIANG , YOUNG KATHERINE , HERMES JEFFREY DONALD , CHEN HELEN , RAEPPEL STEPHANE , MANNION MICHAEL , GAUDETTE FREDERIC , VAISBURG ARKADII , RAHL JUBRAIL , GEORGOPAPADAKOU NAFSIKA , ZHOU NANCY Z
IPC分类号： A61P31/04 , A61K31/67 , A61K31/675 , C07F9/6539 , C07F9/6541 , C07F9/6553 , C07F9/6558 , C07F9/6561
CPC分类号： C07F9/655354 , C07F9/65395 , C07F9/6541 , C07F9/6553 , C07F9/6558 , C07F9/6561
摘要： This invention provides novel ß-lactamase inhibitors of the aryl-and heteroarylsulfonarnidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammomium groups. The compounds inhibit three classes of ß-lactamases and synergize the antibacterial effects of ß-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the ß-lactam antibiotics as a result of the presence of the ß-lactamases. Formula (I) or pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了具有氮基阳离子或季铵基团的芳基和杂芳基磺酰基甲基膦酸酯单酯类的新型β-内酰胺酶抑制剂。该化合物抑制三种类型的β-内酰胺酶，并且与β-内酰胺类抗生素（例如，亚胺培南和头孢他啶的抗菌作用）对抗β-内酰胺抗生素通常具有抗ß-内酰胺抗生素的微生物的协同作用是由于存在β-内酰胺酶。式（I）或其药学上可接受的盐。

4. 发明申请

WO2007139729A8 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 审中-公开
标题翻译： β-乳酸酶的新型磺酰亚胺磷酸盐抑制剂
公开(公告)号：WO2007139729A8
公开(公告)日：2008-02-28
申请号：PCT/US2007011977
申请日：2007-05-21
申请人： MERCK & CO INC , METHYLGENE INC , DININNO FRANK , HAMMOND MILTON L , DYKSTRA KEVIN , KIM SEONGKON , TAN QIANG , YOUNG KATHERINE , HERMES JEFFREY DONALD , RAEPPEL STEPHANE , MANNION MICHAEL , ZHOU NANCY Z , GAUDETTE FREDERIC , VAISBURG ARKADII , RAHIL JUBRAIL , GEORGOPAPADAKOU NAFSIKA
发明人： DININNO FRANK , HAMMOND MILTON L , DYKSTRA KEVIN , KIM SEONGKON , TAN QIANG , YOUNG KATHERINE , HERMES JEFFREY DONALD , RAEPPEL STEPHANE , MANNION MICHAEL , ZHOU NANCY Z , GAUDETTE FREDERIC , VAISBURG ARKADII , RAHIL JUBRAIL , GEORGOPAPADAKOU NAFSIKA
IPC分类号： C07F9/6539 , A61K31/662 , A61P31/04 , C07F9/655 , C07F9/6553 , C07F9/6558
CPC分类号： C07F9/655354 , C07F9/6539 , C07F9/65517 , C07F9/655345 , C07F9/65586
摘要： This invention provides novel ß-lactamase inhibitors of the aryl-and heteroaryl-sulfonamidomethylphosphonate monoester class. The compounds inhibit three classes of ß-lactamases and synergize the antibacterial effects of ß-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the ß-lactam antibiotics as a result of the presence of the ß-lactamases. Formula (I) or a pro-drug or pharmaceutically acceptable salt thereof, wherein: W represents: Formula (II).
摘要翻译：本发明提供了芳基 - 和杂芳基磺酰氨基甲基膦酸酯单酯类的新型β-内酰胺酶抑制剂。该化合物抑制三种类型的β-内酰胺酶，并且与β-内酰胺类抗生素（例如，亚胺培南和头孢他啶的抗菌作用）对抗β-内酰胺抗生素通常具有抗ß-内酰胺抗生素的微生物的协同作用是由于存在β-内酰胺酶。式（I）或其前药或其药学上可接受的盐，其中：W表示：式（II）。

5. 发明申请

WO2008073142A3 NOVEL INHIBITORS OF BETA-LACTAMASE 审中-公开
标题翻译： β-LACTAMASE的新型抑制剂
公开(公告)号：WO2008073142A3
公开(公告)日：2008-10-02
申请号：PCT/US2007011979
申请日：2007-05-21
申请人： MERCK & CO INC , METHLGENE INC , DININNO FRANK , HAMMOND MILTON L , DYKSTRA KEVIN , KIM SEONGKON , TAN QIANG , YOUNG KATHERINE , HERMES JEFFREY DONALD , CHEN HELEN , RAEPPEL STEPHANE , MANNION MICHAEL , GAUDETTE FREDERIC , VAISBURG ARKADII , RAHL JUBRAIL , GEORGOPAPADAKOU NAFSIKA , ZHOU NANCY Z
发明人： DININNO FRANK , HAMMOND MILTON L , DYKSTRA KEVIN , KIM SEONGKON , TAN QIANG , YOUNG KATHERINE , HERMES JEFFREY DONALD , CHEN HELEN , RAEPPEL STEPHANE , MANNION MICHAEL , GAUDETTE FREDERIC , VAISBURG ARKADII , RAHL JUBRAIL , GEORGOPAPADAKOU NAFSIKA , ZHOU NANCY Z
IPC分类号： A61P31/04 , A61K31/67 , A61K31/675 , C07F9/6539 , C07F9/6541 , C07F9/6553 , C07F9/6558 , C07F9/6561
CPC分类号： C07F9/655354 , C07F9/65395 , C07F9/6541 , C07F9/6553 , C07F9/6558 , C07F9/6561
摘要： This invention provides novel ß-lactamase inhibitors of the aryl-and heteroarylsulfonarnidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammomium groups. The compounds inhibit three classes of ß-lactamases and synergize the antibacterial effects of ß-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the ß-lactam antibiotics as a result of the presence of the ß-lactamases. Formula (I) or pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了具有氮基阳离子或季铵基团的芳基和杂芳基磺酰基甲基膦酸酯单酯类的新型β-内酰胺酶抑制剂。该化合物抑制三种类型的β-内酰胺酶，并且与β-内酰胺类抗生素（例如，亚胺培南和头孢他啶的抗菌作用）对抗β-内酰胺抗生素通常具有抗ß-内酰胺抗生素的微生物的协同作用是由于存在β-内酰胺酶。式（I）或其药学上可接受的盐。

6. 发明专利

JP2011105735A Inhibitor of protein tyrosine kinase activity 有权
标题翻译：蛋白酪氨酸激酶活性的抑制剂
公开(公告)号：JP2011105735A
公开(公告)日：2011-06-02
申请号：JP2011010326
申请日：2011-01-21
申请人： Methylgene Inc , メチルジーンインコーポレイテッド
发明人： MANNION MICHAEL , RAEPPEL STEPHANE , CLARIDGE STEPHEN WILLIAM , GAUDETTE FREDERIC , ZHAN LIJIE , ISAKOVIC LJUBOMIR , SAAVEDRA OSCAR MARIO , UNO TETSUYUKI , KISHIDA MASASHI , VAISBURG ARKADII
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/444 , A61K31/5377 , A61P9/00 , A61P11/00 , A61P11/02 , A61P17/00 , A61P27/02 , A61P27/16 , A61P35/00 , A61P35/02 , A61P43/00
CPC分类号： C07D495/04 , C07F9/6561
摘要： PROBLEM TO BE SOLVED: To provide a compound for inhibiting protein tyrosine kinase activity; in particular, to provide a compound, a composition and a method, each for treating cell proliferative diseases and conditions and ophthalmologic diseases, disorders and conditions. SOLUTION: This invention relates to a compound represented by a formula as indicated, its hydrate, its solvate, its pharmaceutically allowable salt, its prodrug, its complex, a racemic and scalemic mixture, its diastereomer and its enantiomer. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：待解决的问题：提供抑制蛋白酪氨酸激酶活性的化合物; 特别地，提供用于治疗细胞增殖性疾病和病症以及眼科疾病，病症和病症的化合物，组合物和方法。本发明涉及由所示的式表示的化合物，其水合物，其溶剂化物，其药学上可允许的盐，其前药，其络合物，外消旋和可比混合物，其非对映异构体及其对映异构体。版权所有（C）2011，JPO＆INPIT

7. 发明公开

EP1957498A4 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING 有权转让
标题翻译： VEGF和HGF受体信号传导抑制剂
公开(公告)号：EP1957498A4
公开(公告)日：2010-10-27
申请号：EP06851548
申请日：2006-05-19
申请人： METHYLGENE INC
发明人： SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY , GAUDETTE FREDERIC , ISAKOVIC LJUBOMIR , WAHHAB AMAL , GRANGER MARIE-CLAUDE , BERNSTEIN NAOMY
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P35/00
CPC分类号： C07D495/04

8. 发明公开

EP2563794A4 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND USE THEREOF TO TREAT OPHTHALMIC DISORDERS 审中-公开
标题翻译：蛋白酪氨酸激酶活性抑制剂及其在治疗眼病中的应用
公开(公告)号：EP2563794A4
公开(公告)日：2013-12-04
申请号：EP11768305
申请日：2011-04-08
申请人： METHYLGENE INC
发明人： RAEPPEL STEPHANE , ZHAN LIJIE , CLARIDGE STEPHEN WILLIAM , RAEPPEL FRANCK , GAUDETTE FREDERIC , VAISBURG ARKADII
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/444 , A61K31/496 , A61K31/5377 , A61P27/02
CPC分类号： C07D495/04 , A61K38/005 , C07D519/00 , C07F9/6561 , C07K5/06
摘要： The invention provides new compounds and compositions thereof. The invention also provides methods for treating ophthalmic diseases, disorders and conditions.
摘要翻译：本发明提供了新的化合物及其组合物。本发明还提供了治疗眼科疾病，病症和病症的方法。

9. 发明公开

EP2563795A4 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY 审中-公开
标题翻译：抑制剂蛋白酪氨酸
公开(公告)号：EP2563795A4
公开(公告)日：2013-10-23
申请号：EP11768307
申请日：2011-04-08
申请人： METHYLGENE INC
发明人： RAEPPEL STEPHANE , RAEPPEL FRANCK , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , GAUDETTE FREDERIC , MANNION MICHAEL , SATO NORIFUMI , YUKI YOHEI , KISHIDA MASASHI , VAISBURG ARKADII
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P27/02 , A61P35/00 , C07D519/00
CPC分类号： C07D495/04 , A61K38/005 , C07D519/00 , C07F9/6561 , C07K5/06

10. 发明专利

NZ602948A Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders 未知
公开(公告)号：NZ602948A
公开(公告)日：2014-09-26
申请号：NZ60294811
申请日：2011-04-08
申请人： METHYLGENE INC
发明人： VAISBURG ARKADII , RAEPPEL FRANCK , ZHAN LIJIE , RAEPPEL STEPHANE , GAUDETTE FREDERIC , CLARIDGE STEPHEN WILLIAM
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/444 , A61K31/496 , A61K31/5377 , A61P27/02
摘要： Disclosed are thieno[3,2-b]pyridine derivatives selected from 3-[(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl]-1-ethyl-3-[2-methoxyethyl]urea, N-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yI)methyl)-N-(2-methoxyethyl)formamide, N-((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-b]pyridin-2-yl)-pyridin-3-yl)methyl)-N-(2-methoxyethyl)acetamide, 1-cyclopropyI-3-(3-fluoro-4-(2-(5-((4-(2-hydroxyacetyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea, (S)-2-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)-2-oxoethyl 2-amino-3-methylbutanoate, 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((2-(methylsulfonyl)ethylamino)methyl)pyridin-2-yl)thieno[3,2-b ]pyridin-7-yloxy)phenyl)urea, 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-((2-hydroxyethyl)(methyl)amino)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea, 1-((2-(7-(4-Isopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b ]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-isopropyl-1-(2-methoxyethyl)urea, N-((2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-2-hydroxy-N-(2-methoxyethyl)acetamide, 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea and 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-morpholinoethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea. Further disclosed is a composition comprising a compound as defined above and a pharmaceutically acceptable carrier, for treating an ophthalmic disease, condition or disorder, wherein the ophthalmic disease, disorder or condition is selected from the group consisting of (a) a disease, disorder or condition caused by choroidal angiogenesis (including age-related macular degeneration), (b) diabetic retinopathy and (c) retinal edema.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式